Navigation Links
New Data Suggests Interferon-Free Therapy Around the Corner for HCV Patients
Date:4/19/2012

men of BI201335, BI207127 and RBV achieved 60% SVR12 after 16 weeks of treatment and up to 70% SVR4 after treatment with a lower BI207127 dose (600mg BID) for 28 weeks.


VITAL-1

  • Pawlotsky J-M, et al 'ALISPORIVIR plus RIBAVIRIN is highly effective as INTERFERON-FREE or INTERFERON-ADD-ON regimen in previously untreated HCV-GT2 or GT3 patients: SVR12 results from VITAL-1 phase 2b study' and the related abstract Alberti A, et al 'ALISPORIVIR (ALV) plus PEG-INTERFERON/RIBAVIRIN (PR) in HCV G1 treatment-experienced patients achieves primary endpoint with superior efficacy at treatment week 12 compared to retreatment with PR'.
  • In Pawlotsky J-M, et al, 88% of treatment-naïve HCV GT2 or 3 patients achieved SVR 12 after treatment with Alisporivir and RBV. In Alberti A, et al, 70% of null non-responders achieved cEVR when treated with Alisporivir, IFN and RBV.

AI444040

  • Sulkowski M, et al 'Potent viral suppression with all-oral combination of DACLATASVIR (ns5a inhibitor) and GS-7977 (ns5b inhibitor), +/-RIBAVIRIN, in treatment-naïve patients with chronic HCV GT1, 2, or 3'
  • Treatment-naïve HCV GT1, 2, and 3 patients given an IFN- and RBV-free once-daily combination of DACLATASVIR and GS-7977 for 24 weeks achieved high rates of early virologic response (HCV RNA detectable at week 4 but undetectable at week 12   EVR) by mITT analysis: 97% EVR in GT1, 90% in GT2 and 3.

The combination of PegIFN-α and ribavirin (RBV) is the current standard of care for chronic HCV[7], but is associated with a number of side effects - including flu-like symptoms, psychiatric manifestations, autoimmune reactions, and hematologic toxicities.[8],[9] Between 20-40% of patients require a dose reduction or temporary interruption in their PegIFN-α and r
'/>"/>

SOURCE European Association for the Study of the Liver
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Journal Article Suggests DermaClose® RC Used in Combination With VAC Therapy Can Dramatically Reduce the Need for Skin Grafting of Fasciotomy Wounds for Combat Related Trauma
2. Grifols Study Suggests Repeated Plasmapheresis May Reduce "Bad" LDL Cholesterol Levels While Increasing "Good" HDL Cholesterol Levels in Some Individuals
3. New Research Suggests That Acthar Reduces Proteinuria in Idiopathic Membranous Nephropathy In Part Through Suppression of Anti-PLA2R Antibodies
4. TRiUS Data Suggests That Testim® Significantly Improved Sexual Function in Hypogonadal Men
5. Help Remedies Suggests People TAKE LESS
6. Research Suggests FORTEO® Significantly Increases Bone Strength
7. Food Allergies Common among Children and Linked to Environmental Allergies and Asthma Later in Life, Suggests Largest-Ever National Allergy Study
8. Leading Rehab Facility Urges Patients Not to Stop Taking Antidepressants After New Study Suggests Increased Risk of Heart Attacks and Strokes
9. New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations
10. Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate
11. Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated With INVEGA® SUSTENNA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)...  Haemonetics Corporation (NYSE: HAE ) ... of its previously announced manufacturing transformation.  ... , Haemonetics has selected Sanmina Corporation (NASDAQ: ... medical devices currently manufactured in Braintree ... of integrated manufacturing solutions, components, products and repair, ...
(Date:6/19/2013)... Dr. Davis Lee , CMIO for PIH Health ... 2013 AMDIS Award, a prestigious recognition saluting excellence and ... "On behalf of Allscripts, I,d like to congratulate Dr. ... efforts to improve patient care and population health," said ... Officer of Allscripts. "We are committed to our partnership ...
(Date:6/19/2013)... , June 19, 2013 The American Association ... from Maryland , announced today the filing ... Washington, D.C. , asking that the scheduled ... for durable medical equipment (DME) be stopped because of serious ... Health and Human Services (HHS) Secretary Kathleen Sebelius ...
Breaking Medicine Technology:Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 2Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 3Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 4Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 5AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 2AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 3AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 4AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 5
... After Ozarelix Was Maintained For ... Up To Six Months, ... Thereafter, IRVINE, Calif., Sept. 5 Spectrum,Pharmaceuticals, Inc., (Nasdaq: SPPI ... Company,s drug candidate for the,treatment of benign prostatic hypertrophy (BPH), at the ...
... Hosts Key Investigator Meeting for European Participants in ... 3 AGENDA Trial Targeting Biomarker-Defined Population, ... (Nasdaq: GNTA ) announced that data from ... plus chemotherapy would be,presented at the opening session ...
Cached Medicine Technology:Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 2Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 3Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 4Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 5Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 2Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 3Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 4Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 5
(Date:6/19/2013)... 19, 2013 PrettySkin4Less announces it is ... serums by top skin care manufacturer EMINENCE to ... of vitamins, minerals and active organic ingredients to promote ... many other beauty products offer. For this reason it’s ... , "I like products that do what they ...
(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...
(Date:6/19/2013)... As Januvia lawsuit ... in courts throughout the U.S., Bernstein Liebhard LLP notes ... held a meeting to discuss the safety of Januvia ... According to a June 12th report from Bloomberg.com, the ... Januvia and similar drugs, following a recent study that ...
(Date:6/19/2013)... is believed to be the largest follow-up record of ... a movement disorder that can cause crippling muscle ... success rates and lasting benefits. , Michele Tagliati, MD, ... Medical Center,s Department of Neurology, and Ron L. Alterman, ... Israel Deaconess Medical Center in Boston, published the study ...
(Date:6/19/2013)... study reveals significant disparities between minority and white ... treatment programs. Moreover, these disparities vary widely from ... that for most states there,s something amiss," says ... biostatistics. "There are strong racial and ethnic disparities ... abuse treatment programs successfully, and those disparities are ...
Breaking Medicine News(10 mins):Health News:PrettySkin4Less Launches New Innovative Skin Serums with Active Organic Ingredients to World Wide Consumer Base 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3
... PharmaTech (Cayman) Inc.,(NYSE: WX ), a leading ... with operations in China and the,United States, today announced ... WuXi PharmaTech Board of Directors. , ... Dr. Ge Li, WuXi,s Chairman and Chief ...
... Receptors and Cell Signaling at UH and MethodistHOUSTON, Feb. ... of a $5.5 million grant to the University ... (ETF). As a result of the ETF grant, UH ... to carry out laboratory research and to create next-generation ...
... today for the event to take place November 21-22 ... 5 The Leukemia & Lymphoma Society (LLS) and ... officials, announcement today granting the two organizations permission to ... November 21-22, 2009. The event, Women,s Running ...
... W.Va., Feb. 5 ReBuilder Medical Technologies, Inc. (Pink ... treatments for diabetic peripheral neuropathy and ... increase in sales for the month of January. (Logo: ... appear to be recession proof and this monthly sales ...
... unemployment rate facing Americans with disabilities , WASHINGTON, Feb. ... the first time, release employment and unemployment data on ... information will assist the nation in understanding how changing ... it is widely believed that this group typically faces ...
... February 5, 2009 Narcotics have an irreversible effect ... illness, according to Dr. Stphane Potvin of the Universit ... Louis-H Lafontaine Hospital. , According to his research, ... suffer from drug addiction. The study has shown that ...
Cached Medicine News:Health News:WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board 2Health News:WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board 3Health News:Internationally Acclaimed Researcher Joins UH Faculty 2Health News:Internationally Acclaimed Researcher Joins UH Faculty 3Health News:Internationally Acclaimed Researcher Joins UH Faculty 4Health News:Internationally Acclaimed Researcher Joins UH Faculty 5Health News:Internationally Acclaimed Researcher Joins UH Faculty 6Health News:The Leukemia & Lymphoma Society and Women's Running Magazine Join Forces to Launch New All-Women Half Marathon in St. Petersburg 2Health News:ReBuilder Medical Technologies, Inc. (RBRM) Announces Sales Increase In Jan. 09 2Health News:U.S. Labor Department to begin new monthly data series on people with disabilities from Current Population Survey on Feb. 6 2
... is an FDA approved rapid ... blood test used to aid ... infection. This CLIA waived test, ... antibodies to HIV-1, requires only ...
... The Acceava Mononucleosis test provides ... Mononucleosis with a simple procedure that ... Side-by-side evaluations with competitive products will ... These attributes enable you to deliver ...
Unitary one step immuno-chromatographic assay for the qualitative detection of infectious mononucleosis heterophile antibodies in human serum, plasma or whole blood....
... Influenza A+B test allows for the ... A and type B antigens directly ... nasal aspirate specimens. The test is ... rapid differential diagnosis of acute influenza ...
Medicine Products: